Daybu (trofinetide), marketed as Daybue and Daybue Stix in the U.S., could become the first treatment for Rett syndrome neurobehavioral issues in the European Union, if the European Commission approves a committee’s recommendation. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive…
Information about Rett syndrome
About
Rett syndrome is a rare genetic disorder that mostly affects females. The disease is characterized by normal early development, followed by slowed growth and a loss of motor control. Learn more about the disease here.
Causes
Most cases are caused by a mutation in the MECP2 gene. Scientists have identified mutations in CDKL5 and FOXG1 genes in those who have atypical or congenital Rett. Learn more about what causes the disease here.
Symptoms
Rett syndrome is associated with problems in cognitive, sensory, emotional, and motor skills, and across the nervous system that controls involuntary (or autonomic) functions. Learn more about the symptoms of the disease here.